{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:54:14Z","timestamp":1785419654799,"version":"3.56.0"},"reference-count":33,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T00:00:00Z","timestamp":1624838400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>\u00a0Advanced biliary tract cancer (ABTC) is a highly aggressive malignancy, with a 5\u2010year overall survival of\u00a0&lt;\u00a010%. Although preliminary evidence suggests a role of targeted treatments or immunotherapy in a subset of patients, chemotherapy remains the standard second\u2010line treatment in the majority. We conducted a pilot study of second\u2010line chemotherapy with capecitabine and nab\u2010paclitaxel after failure of gemcitabine and platinum.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Eligible patients had histologically proven, unresectable biliary tract cancer, which had progressed on a gemcitabine\/platinum doublet. In this single\u2010arm, multicenter trial, all patients received capecitabine (825\u00a0mg\/m<jats:sup>2<\/jats:sup> bd PO D1\u201014 q21d) and nab\u2010paclitaxel (125\u00a0mg\/m<jats:sup>2<\/jats:sup> IV D1,8 q21d) until progression or unacceptable toxicity. The primary objective was feasibility of delivering the proposed regimen, with secondary objectives of disease control measures and QOL outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Ten patients were enrolled between 2015 and 2016 from four cancer centers in NSW. Treatment was generally well tolerated with grade III toxicities in five patients (including infection, cholangitis, obstruction, and intestinal perforation) and no grade IV toxicity. Median treatment duration was 4.3 months, with a disease control rate of 80% (8\/10), and median progression\u2010free and overall survival of 5.7 and 12.1 months, respectively. Quality of life data and specimens for translational research have been collected.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our pilot study demonstrates that combination of capecitabine and nab\u2010paclitaxel is feasible as a second\u2010line treatment in ABTC. Adequate safety and promising early efficacy signals make further assessment of the combination in a formal phase II or III trial reasonable. Clinical trial information: ACTRN12615000504516.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ajco.13599","type":"journal-article","created":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T12:02:44Z","timestamp":1624881764000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Combination chemotherapy with NAB<sup>\u00ae<\/sup>\u2010paclitaxel and capecitabine for patients with advanced biliary tract cancer (NAP\u2010CAPABIL Pilot Study)"],"prefix":"10.1111","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9470-314X","authenticated-orcid":false,"given":"Rachel","family":"Woodford","sequence":"first","affiliation":[{"name":"St George Hospital  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Brungs","sequence":"additional","affiliation":[{"name":"Illawarra Health and Medical Research Institute and School of Medicine University of Wollongong  Wollongong New South Wales Australia"},{"name":"Illawarra Cancer Care Centre The Wollongong Hospital  Wollongong New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly","family":"Leighton","sequence":"additional","affiliation":[{"name":"Illawarra Cancer Care Centre The Wollongong Hospital  Wollongong New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2653-1657","authenticated-orcid":false,"given":"Peter","family":"Grimison","sequence":"additional","affiliation":[{"name":"Chris O'Brien Lifehouse  Sydney New South Wales Australia"},{"name":"NHMRC Clinical Trials Centre The University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin M.","family":"Sjoquist","sequence":"additional","affiliation":[{"name":"St George Hospital  Sydney New South Wales Australia"},{"name":"NHMRC Clinical Trials Centre The University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therese","family":"Becker","sequence":"additional","affiliation":[{"name":"Centre for Circulating Tumour Cell Diagnostics and Research Ingham Institute for Applied Medical Research  Liverpool New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Robinson","sequence":"additional","affiliation":[{"name":"Illawarra Cancer Care Centre The Wollongong Hospital  Wollongong New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val","family":"Gebski","sequence":"additional","affiliation":[{"name":"NHMRC Clinical Trials Centre The University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Wilson","sequence":"additional","affiliation":[{"name":"NHMRC Clinical Trials Centre The University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine","family":"Chantrill","sequence":"additional","affiliation":[{"name":"Illawarra Cancer Care Centre The Wollongong Hospital  Wollongong New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morteza","family":"Aghmesheh","sequence":"additional","affiliation":[{"name":"Illawarra Health and Medical Research Institute and School of Medicine University of Wollongong  Wollongong New South Wales Australia"},{"name":"Illawarra Cancer Care Centre The Wollongong Hospital  Wollongong New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,6,28]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.23762"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOG.0b013e32835d9dea"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908721"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a010676"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605779"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.11.024"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.08.003"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.12638"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.190"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu162"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2016-000152"},{"key":"e_1_2_9_13_1","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1200\/JCO.2019.37.15_suppl.4003","article-title":"ABC\u201006 | A randomised phase III, multi\u2010centre, open\u2010label study of active symptom control (ASC) alone or ASC with oxaliplatin \/5\u2010FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced \/ metastatic biliary tract cancers (ABC) previously\u2010treated with cisplatin\/gemcitabine (CisGem) chemotherapy","volume":"37","author":"Lamarca A","year":"2019","journal-title":"J Clin Oncol"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz394.027"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0930"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-013-2106-0"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-010-9553-9"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1159\/000339499"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg281"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i7.810"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.4006"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1016209901417"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199902000-00019"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3277"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.5742"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2016.05.01"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz058"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0270"},{"issue":"2","key":"e_1_2_9_29_1","first-page":"234","article-title":"Phase II trial of capecitabine plus nab\u2010paclitaxel in patients with metastatic pancreatic adenocarcinoma","volume":"7","author":"Scheithauer W","year":"2016","journal-title":"J Gastrointest Oncol"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2016.01.03"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.64"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2017.08.002"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.108"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.032"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.13599","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajco.13599","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.13599","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T16:20:23Z","timestamp":1692807623000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.13599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,28]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1111\/ajco.13599"],"URL":"https:\/\/doi.org\/10.1111\/ajco.13599","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,28]]},"assertion":[{"value":"2021-02-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}